Company profile
Aquestive Therapeutics, Inc.
AQST · Nasdaq (Nasdaq-listed (AQST) pharmaceutical company (Warren, NJ) marketing Sympazan (clobazam) oral film for Lennox-Gastaut-syndrome seizures. Its SEC EDGAR CIK (0001398733) matches the identifier already listed alongside this sponsor's example NCT record, confirming the entity. Not currently on our roster. Sources: https://clinicaltrials.gov/study/NCT03179891 ; https://data.sec.gov/submissions/CIK0001398733.json ; https://www.sec.gov/Archives/edgar/data/1398733/000162828023014914/aqst-q1x2023xex991earnings.htm Entity resolved by asset-pipeline-v2.)
Share price · AQST
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
Clobazam (Sympazan)(Sympazan) | Approved | GABA-A receptor (benzodiazepine site)Small molecule | Epilepsy |
Diazepam (Libervant)(Libervant) | Phase 3 | GABA-A receptorSmall molecule | Epilepsy |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Unlock insider transactions
Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Unlock institutional holders
Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.